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Consumer interest in genetic and genomic testing is growing rapidly, with more than 26 million Americans having purchased
direct-to-consumer genetic testing services. Capitalizing on the increasing comfort of consumers with genetic testing outside the
clinical environment, commercial vendors are expanding their customer base by marketing genetic and genomic testing services,
including testing for pharmacogenomic and pathogenic variants, to employers for inclusion in workplace wellness programs. We
describe the appeal of voluntary workplace genomic testing (wGT) to employers and employees, how the ethical, legal, and social
implications literature has approached the issue of genetic testing in the workplace in the past, and outline the relevant legal
landscape. Given that we are in the early stages of development of the wGT market, now is the time to identify the critical interests
and concerns of employees and employers, so that governance can develop and evolve along with the wGT market, rather than
behind it, and be based on data, rather than speculative hopes and fears.
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Consumer interest in genetic and genomic testing is growing
rapidly, with more than 26 million Americans having purchased
direct-to-consumer (DTC) genetic testing services1. The global
consumer genetic testing market is anticipated to exceed $2.5
billion by 20251–4. Capitalizing on the increasing comfort of
consumers with genetic testing outside the clinical environment, commercial vendors are expanding their customer bases
by marketing genetic and genomic testing services, including
testing for pharmacogenomic and pathogenic variants, to
employers for inclusion in workplace wellness programs. For
the purposes of this paper, voluntary workplace genomic
testing (wGT) refers to both genetic and genomic testing
offered by vendors through voluntary workplace wellness
programs, as the full range of testing offered through such
programs has not been robustly studied to date. Workplace
wellness programs commonly include features like health risk
assessments, biometric testing and screening, smoking cessation programs, and gym and health-club memberships5. We
describe the potential appeal of wGT to employers and
employees, how the ethical, legal, and social implications
(ELSI) literature has approached the issue of workplace genetic
testing in the past, and outline the current relevant legal
landscape in the United States (US). Given that we are in the
early stages of development of the wGT market, now is the
time to identify the critical interests and concerns of employees and employers, so that governance can develop and
evolve along with the wGT market, rather than behind it, and
be based on data and evidence, rather than speculative hopes
and fears.

THE APPEAL OF GENETIC TESTING AS A WELLNESS BENEFIT
In the US, employers often take keen interest in the health of their
employees because most Americans receive their health insurance
through their workplace6. Further, many employers are selfinsured or self-funded, choosing to directly ﬁnance some or all of
their employee health services and beneﬁts instead of purchasing
health insurance for employees, meaning that the employer is
ﬁnancially responsible for the healthcare claims of their employees. According to the 2020 Employer Health Beneﬁts Survey
published by the Kaiser Family Foundation, 67% of employees
across all surveyed ﬁrms were in a self-funded plan. At ﬁrms with
5000 or more employees, 94% of employees were in a self-funded
plan7. Furthermore, employer-sponsored health plans cover more
than 157 million people in the US8.
Advances in genetic medicine have improved our ability to
predict, prevent, and treat certain genetic conditions9–11. DTC
testing, elective return of actionable “secondary” ﬁndings (e.g.,
hereditary cancers and certain cardiovascular conditions) following genomic testing according to American College of Medical
Genetics and Genomics (ACMG) guidelines, and expanded efforts
to engage family members after a patient’s genetic diagnosis
(cascade screening) are increasing the numbers of individuals
receiving genetic and genomic test results12–14. wGT could push
these numbers higher, especially among generally younger and
healthier populations who may not have cause or opportunity to
pursue genetic testing through a clinical care infrastructure. Those
who promote wGT suggest that such testing has the potential to
lower employer healthcare costs as a result of: (1) employees
becoming more informed about disease risks, making lifestyle
changes, increasing preventive screenings or pursuing other
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interventions to reduce disease risks15; and (2) employers using
aggregate employee test data to add other beneﬁts that could
potentially mitigate disease risks16.
A number of commercial vendors are marketing wGT services to
employers17; however, it is currently unknown how many
companies are actually offering wGT within their workplace
wellness programs, what kind of testing is being offered, and
whether the programs include services beyond mere testing, such
as pre- or post-test genetic counseling. Further, little is known
about employers’ motivations to provide wGT or how they access
and utilize the resulting aggregate data. What we do know comes
largely from press releases and media reports18,19. For example,
executives at some US companies offering wGT have described
this offering as “creating goodwill” with employees and being “a
differentiator” that sets them apart from competing employers20.
However, we have only limited data in the US or elsewhere on
employee perspectives and concerns about wGT that would
enable us to evaluate such claims21.
In a recent survey of employees at a biomedical research
institution in the US, participants provided their views on wGT
after being presented with three hypothetical scenarios for
accessing genetic testing: (1) in the participant’s doctor’s ofﬁce;
(2) a workplace setting, and (3) via DTC testing. Of the 594
respondents, 70% of respondents indicated that they would prefer
genetic testing in the workplace over a doctor’s ofﬁce or DTC
setting, though the survey did not solicit rationale. In addition,
over 60% of respondents wanted to know about relevant laws and
policies in place to protect their privacy and conﬁdentiality21. It is
important to note that the participants in this study were
employed at a biomedical research institution that speciﬁcally
focuses on genomics, and their views may not be representative
of the broader population of employees’ views towards wGT.
Further research is needed with employees at a range of diverse
organizations. Previous research on employee perspectives
regarding wGT found that employees have a desire to learn
about their genetic information, and want a choice regarding who
controls, stores, and has access to their genetic information22. For
example, in one survey of university health center employees,
respondents expressed strong interest in learning about their own
genetic information while also rating privacy and conﬁdentiality
protections as very important22. The participants also indicated
that including this information in their employee health records
and insurance ﬁles was unacceptable, as was using their
identiﬁable information in genetic research22.
Additionally, a 2017 Wamberg Genomic Consumer Survey of
536 US consumers with employer-sponsored health insurance
reported that 65% of employees would be interested in genetic
testing if their employers offered easy and affordable access with
strict privacy and data ownership control, allowing test result
access only to the employee and their doctor23. This latter
stipulation underscores the privacy concerns employees have
about wGT. Regardless of context, it remains the case that many
people and policies, including the Genetic Information Nondiscrimination Act (GINA), regard genetic information as a unique
category of health information, in that it is intrinsic, predictive,
probabilistic, and has relevance for close genetic relatives24. In
part due to these characteristics, policies providing consumer
protection speciﬁc to genetic information enjoy broad support25.
HISTORICAL PERSPECTIVES ON GENETIC TESTING IN THE
WORKPLACE
While wGT is a relatively new phenomenon, employer use of
genetic testing and screening (and associated ethical analysis of
the practice) has been ongoing since at least the 1990s, with an
initial focus on genetic monitoring and genetic vulnerability
screening to mitigate employee risk to workplace hazards6,26–28.
While the terms are sometimes used interchangeably, genetic
npj Genomic Medicine (2022) 5

monitoring includes frequent employee testing to determine the
effects of toxic substances on employee health (e.g., DNA testing
to measure carcinogen exposure to assess cancer risk)29, whereas
genetic vulnerability screening includes testing an unselected
group of employees once to identify workers with genetic
susceptibilities that might make them more vulnerable to harm
in the workplace (e.g., G6PD deﬁciency that increases sensitivity to
oxidative stress, or sickle cell carriers who face increased risk in
hypoxic environments)26,27. Since these very early experiences,
concerns have been raised about the ELSI of such testing30, and
these potential issues have increased with the expansion of
genetic knowledge gained over the intervening decades.
A main ethical concern raised by historical workplace genetic
vulnerability screening is that while employers argued that this
screening could enable them to safeguard against workplacerelated illness, it might also enable them to avoid legal liability for
illnesses resulting from workplace hazards that could be attributed
to an employee’s genetic predisposition26. Additionally, due to the
newfound knowledge of genetic causes for some diseases,
ethicists also raised the concern that this information could be
used to discriminate against historically marginalized populations
(e.g., by mandating sickle cell testing), and that a positive
screening result could both facilitate discrimination and exacerbate stigma28. Historically, some organizations, including parts of
the US military, tested individuals for sickle cell trait (SCT), for
example, to restrict access to certain kinds of military service and
beneﬁts for individuals found to have the trait. However, due to
conﬂicting evidence on the relationship between SCT and jobrelated risks, and concerns about genetic and racial discrimination,
the testing as originally practiced was discontinued31. Furthermore, potential false positive and false negative screening results
(the latter of which were more common in early genetic
screening/testing) exacerbated these concerns28.
Early discussions of genetic vulnerability screening in the
workplace raised the possibility that such screening could be
completed as part of the pre-employment hiring process, similar
to pre-employment use of other medical information and testing.
The Americans with Disabilities Act (ADA), which was passed in
1990, regulates pre-employment medical testing in order to limit
the potential for discrimination32. Several key legal cases have
demonstrated the potential for discrimination and unethical use
of screening for genetic conditions in the workplace6. In NormanBloodsaw v. Lawrence Berkeley Labs (1998), employees sued their
employer for medical testing of employee blood and urine
samples without their knowledge or consent. In addition to broad
syphilis testing of employees, Black employees had been tested
for sickle cell carrier status, and women had been tested for
pregnancy. The 9th Circuit Court of Appeals reversed summary
judgment for the defendants on the grounds of the 4th
Amendment’s prohibition of unreasonable searches and seizures.
Additionally, the court held that Title VII of the Civil Rights Act
(which prohibits employment discrimination based on race, color,
religion, sex, and national origin), allowed the plaintiff’s claims that
they should not be forced to undergo genetic testing by an
employer during the pre-screening process33. Perhaps the most
prominent case is the Equal Employment Opportunity Commission’s (EEOC) 2001 suit against the Burlington Northern Railway
Company alleging violations of the ADA34–36. Burlington Northern
had been requiring blood samples from all employees who
claimed they developed work-related carpal tunnel syndrome to
determine whether they had a rare genetic predisposition to this
condition, a ﬁnding that might help the employer avoid worker
compensation claims costs. However, the company did not tell
their employees that their samples would be used for genetic
testing6,27,29,37. This case settled for $2.2 million38 and demonstrates the ﬁnancial risk employers may face for inappropriate use
of genetic testing. While this is critical background for a discussion
of genetic and genomic testing in the workplace, it is important to
Published in partnership with CEGMR, King Abdulaziz University
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note that how we use the language of wGT has changed
dramatically since this early experience.
GENETIC TESTING WITHIN WORKPLACE WELLNESS PROGRAMS
In the 1970s, employers began offering workplace wellness
programs promoting healthy behaviors among their employees39
to reduce health costs and to improve employee well-being and
work productivity. The Health Insurance Portability and Accountability Act (HIPAA) in 1996 and Affordable Care Act (ACA) in
2010 set rules allowing for the use of workplace wellness programs.
While both these laws prohibit health plans from adjusting
premiums based on health status, they have an exception for
wellness programs. The laws arguably encourage wellness programs by allowing employers to incentivize employee participation.
After the implementation of the ACA, some wellness programs offer
incentives or impose penalties that are equal to 30% of the cost of
health insurance premiums under the employer’s plan, and as high
as 50% for smokers. This can translate to the gain or loss of
thousands of US dollars for individuals and families alike16,40, raising
concerns that these programs can be coercive41.
wGT could ﬁt well into workplace wellness programs since
genetic and genomic testing may offer employees the opportunity
to identify genetic risks and mitigate or prevent future disease (and
potentially, associated healthcare costs). Indeed, a growing number
of employers are offering, or considering offering, wGT as part of
their wellness programs17,20. However, wGT brings with it both
previously identiﬁed and new ELSI concerns. In response, some ELSI
researchers focusing on genetic testing in the workplace have
shifted their work from genetic monitoring and vulnerability
screening to employee workplace wellness programs42. Given that
the US differs with respect to the structure of health insurance and
healthcare as compared to other countries, many issues in this
space are of unique concern in the US. Differences such as the lack
of a national health system, very high healthcare costs, the
fragmentation of rules of healthcare regulation, and the distribution
of insurers and employers across a large number of states, shape
risks, beneﬁts, and incentives for such programs.
Beyond the narrow category of workplace wellness programs
that offer genetic testing, workplace wellness programs generally
inspire critique. While many employers argue that workplace
wellness programs can lead to healthier employees and lower
costs for employers, this is not necessarily supported by currentlyavailable data41,43. Studies and critiques of these programs have
suggested that they do not address key employer concerns such
as absenteeism44, healthcare coverage costs, or unhealthy
employee behavior38,45, but rather serve to shift the cost of
healthcare coverage from employers to employees46 by establishing rewards/penalties linked to health insurance premium levels.
Additionally, there is worry that employees may forgo any
concerns about the long-term risks associated with wellness
programs (e.g., related to privacy and discrimination) in order to
beneﬁt from near-term ﬁnancial incentives or to avoid penalties.
Many of these overall concerns raised by workplace wellness
programs could also apply to wellness programs that include wGT.
One issue unique to wGT relates to genetic privacy. The public
are wary of potential misuse of their genetic information—public
polling in 2018 revealed that 47% of respondents who had
undergone DTC genetic testing (or whose family members had
done so) expressed concerns about genetic privacy47. Genetic
testing within an employment setting itself could potentially
heighten these privacy concerns if there is not adequate protection
for employees’ information and employment26.
LEGAL LANDSCAPE
In 2008, the US Congress passed GINA, a law prohibiting employers
from using genetic information, broadly deﬁned, for decisions
Published in partnership with CEGMR, King Abdulaziz University

regarding hiring, ﬁring, promotion, or length of employment48. The
law also prohibits covered health insurers from setting eligibility
and premium or contribution amounts for health insurance based
on genetic information. It does not, however, provide protections in
the contexts of disability, long-term care, or life insurance27.
Notably, GINA prohibits employers and health insurers from
collecting genetic information; however, there are exceptions to
this rule for certain cases, including monitoring one’s genetic
information for changes due to exposure of toxic substances in the
workplace and for voluntary workplace wellness programs49.
Current GINA regulations generally state that a program is only
voluntary if there is no incentive or penalty associated with
providing genetic information to the employer50. Additionally, GINA
only allows employers to access aggregate genetic information
(rather than individual-level data) collected from employees in the
wellness program. However, as is discussed further below, there
have been recent efforts by regulators and Congress alike to alter
this rule. While there are several other federal laws and policies that
provide protections for employees in the context of voluntary
workplace wellness programs, they are not speciﬁc to one’s private
genetic information (see Table 1) (e.g., ADA, HIPAA, etc.)33,51.
Currently, it is unclear whether the complex web of federal and
state laws that regulate medical information privacy, discrimination, and group health insurance coverage in employment—such
as GINA, the ACA, the ADA, and HIPAA—actually ensure employee
protections against inappropriate use or misuse of wGT by
employers and insurance carriers25,52,53, such as accessing
individual test results to inform employment decisions or increase
life insurance premiums due to genetic predispositions.
Efforts have been made to put legal guardrails around the use
of genetic information in employment and insurance markets to
provide some protections for individuals40. However, many
commentators feel these efforts have been inconsistent and
inadequate27. The international landscape is unclear, as there is
little relevant literature to date on wGT as described in this paper,
and what literature exists is not recent54.
EMERGING POLICIES
While experts recognize the potential beneﬁts of wGT (e.g., testing
for clinically-actionable mutations) for the employers’ overall
preventive health strategy55, it is not yet clear if the beneﬁts
outweigh the risks for employees. In the absence of federal
regulation providing guidance for employers or protections for
employees there is some support for voluntary guidelines6,42
regarding implementation of wGT. For example, a 2010 statement
by the American College of Occupational and Environmental
Medicine (ACOEM) on Genetic Screening in the Workplace, argues
that while genetic testing of the sort being offered through wGT
has the potential to inform prevention and treatment approaches
by way of pharmacogenomic, susceptibility, and diagnostic
testing, it must be paired with guiding ethical and legal principles,
scientiﬁc validity of wGT tests, and discussion of results with a
trained health professional56.
Congress waded into the debate in 2017, with the introduction of
HR 131357. This bill would have allowed employers to incentivize or
penalize employees for their decisions to disclose genetic information
in a wellness program. The allowable incentive or penalty would have
been up to 30% of health coverage costs, thus mirroring current
incentives allowed by the ACA for general wellness programs.
Additionally, it arguably would have allowed employers to collect
individual-level data about employees’ private genetic or medical
information within the context of a voluntary wellness program58.
This would have thus signiﬁcantly diminished employees’ genetic
privacy rights. Professional societies such as the American Society of
Human Genetics (ASHG) and the ACMG opposed this bill that sought
to exempt workplace wellness programs from GINA and the ADA59,60.
npj Genomic Medicine (2022) 5
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Table 1.

US laws regulating workplace wellness programs.

Law

Legal protections

Health Information Portability and Accountability Act ● HIPAA’s Privacy Rule safeguards the privacy of protected health information, but only covers
(HIPAA) (1996)
healthcare providers, health plans, health care clearinghouses and their business associates.
If the employer’s health plan is administering the workplace wellness program, HIPAA’s
Privacy Rule would apply
● Another part of HIPAA creates antidiscrimination laws related to setting premiums on the
basis of health status (discussed further under the ACA)
Affordable Care Act (ACA) (2010)

● The ACA amended HIPAA to alter its antidiscrimination protections
● Together, the laws prohibit group and individual health plans from considering an
individual’s health status when setting premiums; however, there is an exception for
wellness programs
● The ACA set the allowable amount wellness programs can leverage as an incentive/penalty
for participation at 30% of the cost of the health plan (50% for smoking cessation programs)
● The ACA and HIPAA set other rules for wellness programs, depending on the type of
program, like who it must be offered to and how often a participant must be able to qualify
for an incentive

Americans with Disabilities Act (ADA) (1990)

● The ADA restricts an employer from collecting medical information about an employee,
with some exceptions
● One exception is for voluntary wellness programs
● Voluntary is not deﬁned by law and there has been debate about what the rules regarding
allowable incentives should be
● GINA prohibits employers from collecting genetic information, with some exceptions
● One exception is for voluntary wellness programs
● However, unlike the ADA, GINA deﬁned voluntary to state that no incentives could be
offered to provide genetic information
● GINA prohibits employers from accessing individual-level genetic data in wellness
programs; they can only access aggregate data

Genetic Information Nondiscrimination Act
(GINA) (2008)

Finally, the EEOC under the Trump Administration proposed
rules that would have altered the protections of GINA in regard to
workplace wellness programs61. For example, the proposed rules
would have allowed rewards to incentivize individuals to share
their genetic information, thus increasing concerns about coercion
and the risks of breaches of privacy and the possibility of
discrimination for employees. Of note, employers would not be
required to share the type of employee health information they
would be privy to or how they would use the information.
However, as of July 2021, any further action on these proposed
rules has been paused by the Biden Administration62.
THE NEED FOR FURTHER ELSI RESEARCH ON WGT
While two existing commentaries discuss wGT17,63 and address
many of the concerns highlighted above55,64, they focus primarily
on the vendors offering the testing and the employers contracting
with them. One of these, Stakeholders Assessing Genetics with
Employers (SAGE), is a 2019 federally-funded project that provides
some framework and context for conducting research on wGT63
and created a checklist for employers considering wGT. The four
areas for consideration are: (1) Deﬁning wellness program goals;
(2) Speciﬁc types of genetic tests to be offered to employees; (3)
Legal and policy considerations to mitigate liability risks and
choosing a reputable vendor; and (4) Types of evidence employers
should request to ensure that their wGT goals are achieved.
Ultimately, there are many questions to be answered and little
published research exploring the intersection of workplace
wellness programs and genetic testing17,41,65.
Given the expectation that wGT will become more prevalent in the
future, there is an urgent need to understand its beneﬁts and risks.
There also remains a need for empirical data to address the concerns
raised by wGT and potential policy safeguards. It will also be
important to understand concrete issues such as whether there are
differences in implementing wGT in different settings, including the
academic, non-proﬁt, and corporate settings, and within small versus
large companies (e.g., in whether or not genetic counseling is offered
or how aggregate data are accessed and used). Our group has
npj Genomic Medicine (2022) 5

undertaken an initial step to study the ELSI issues surrounding wGT
in real world settings and to elicit the perspectives of a broader
repertoire of stakeholders—including employees, employers, and
other relevant groups—whose perspectives are necessary for a fully
informed view of wGT’s risks and beneﬁts. Our current NHGRI-funded
mixed-methods study aims to address the gaps in understanding of
the wGT landscape and provide much needed empirical data to
inform a normative assessment of wGT.
Recognizing that existing studies on wellness programs report
minimal short-term beneﬁts and do not account for wGT, our
study will provide a comprehensive assessment of wGT from both
the employee and employer perspectives—advancing an
evidence-based approach to policy and decision making in this
area of genetic testing. By undertaking a multifaceted impartial
analysis, we hope to provide foundational information and
insights to inform decision making for wGT, including (if
appropriate) considerations for its implementation, so as to
maximize its positive impact on individuals, employers, and
society alike, while minimizing harm.
CONCLUSION
Genetic testing offered outside the clinical setting is affordable
and accessible to a large proportion of the population. US
employers are beginning to offer genetic testing to their
employees as part of their voluntary workplace wellness
beneﬁts, though it is unclear how widespread this practice is
or will become. While this practice is in its infancy, it is
important to consider the implications of wGT for clinical care,
including outreach to genetic counselors, clinical geneticists,
clinical assessment, follow-up, and management. Today’s wGT
through commercial third-party vendors is substantially different from the historical model focused on genetic monitoring
and vulnerability screening. Given this shift, there are new ELSI
and policy concerns that have arisen; however, there is little to
no research currently being conducted to assess these
concerns. At this time, it is still unclear whether Pandora’s Box
of wGT will produce beneﬁts or risks and for whom. Our hope is
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that our study and the work of others will begin to address this
question while there is still time to shape the outcome. If wGT
becomes more widespread, as we predict, it is critical to have
conceptual and empirical analyses of the risks and beneﬁts to
inform policy recommendations designed to maximize positive
impact on individual health, employers, and society alike, while
minimizing harm.
Received: 15 July 2021; Accepted: 9 December 2021;
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